Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusAGEN -2.32%43 Gross Margin % is 57.24% as of Jun. 2026. GuruFocus rates AGEN with a GF Score™ of 43/100 and a GF Value™ of $3.78 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 734 Biotechnology companies, Agenus ranks worse than 55.45% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Agenus's Gross Profit for the
three
months ended in Jun. 2026 was $19.8 Mil. Agenus's Revenue for the
three
months ended in Jun. 2026 was $34.5 Mil. Therefore, Agenus's Gross Margin % for the quarter that ended in Jun. 2026 was 57.24%.
The historical rank and industry rank for Agenus's Gross Margin % or its related term are showing as below:
AGEN'
s Gross Margin % Range Over the Past 10 Years
Min: -320.73 Med: -58.24 Max: 56.04
Current: 56.04
During the past 13 years, the highestGross Margin % of Agenus was 56.04%. The lowest was -320.73%. And the median was -58.24%.
AGEN's Gross Margin % is ranked worse than 55.45% of 734
companies
in the Biotechnology industry
Industry Median: 60.915
vs AGEN: 56.04
Agenus had a gross margin of 57.24% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Agenus was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Agenus had a gross margin of 57.24% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Agenus Gross Margin % Related Terms
Agenus Gross Margin % Historical Data
* Premium members only.
The historical data trend for Agenus's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AGEN vs FULC, IRD, TTRX: Gross Margin % Comparison
For the Biotechnology subindustry, Agenus's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Agenus's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Agenus (AGEN) has a Gross Margin % of 57.24% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Agenus and its competitors. According to the industry distribution chart, Agenus ranks #407 out of 734 companies in the Biotechnology industry, placing it in the top 55.4%.
Is Agenus' Gross Margin % too high?
Agenus' current Gross Margin % is 57.24%. The Biotechnology industry median Gross Margin % is 60.92. Agenus' value of 57.24% is 6% below this industry median. Based on the distribution chart, Agenus ranks #407 out of 734 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Agenus has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' Gross Margin % compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #407 out of 734 companies for Gross Margin %. This places Agenus in the lower half of its industry. The industry median Gross Margin % is 60.92. Agenus' value of 57.24% is 6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agenus's current Gross Margin % of 57.24% is 6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Agenus and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agenus's current Gross Margin % is 57.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (AGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.78, compared to a current price of $7.16 — trading 89.3% above its estimated fair value. The current Gross Margin % is 57.24% and 6% below the Biotechnology industry median of 60.92. Agenus' overall GF Score™ is 43/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Agenus (AGEN), the current Gross Margin % is 57.24% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (AGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of $7.16 is trading 89.3% above its estimated GF Value™ of $3.78.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for AGEN:
Gross Margin %: 57.24%
GF Value™: $3.78 vs. price of $7.16 (89.3% above fair value)
Industry Position: 6% below the Biotechnology median (#407 of 734)
No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score
Get the complete analysis for AGEN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGEN has been successfully added to your 
